Optimizing HIV Prevention Among Opioid-Dependent Persons
优化阿片类药物依赖者的艾滋病毒预防
基本信息
- 批准号:10652562
- 负责人:
- 金额:$ 18.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-15 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAcquired Immunodeficiency SyndromeAddressAdherenceAdoptionAmericanAnalgesicsApplications GrantsBehavior TherapyBehavioralCaringCharacteristicsClinicalCollaborationsCommunicable DiseasesCommunitiesComplementDisease OutbreaksEducational StatusEvidence based interventionFaceFundingFutureGoalsGrantHIVHIV InfectionsHIV riskHealthHealth PersonnelHealth PromotionHealth behaviorImpaired cognitionIncubatorsIndividualInjectableInjecting drug userInstitutionInterdisciplinary StudyInternationalInterventionIntervention TrialK-Series Research Career ProgramsLettersMalaysiaMentorsMentorshipNational Institute of Drug AbuseNeedle-Exchange ProgramsNeurocognitive DeficitOhioOpiate AddictionOpioidPatientsPersonal SatisfactionPersonsPharmaceutical PreparationsPharmacotherapyPoliciesPositioning AttributePreventionPrevention strategyProcessPublic HealthResearchResearch PersonnelRisk BehaviorsRisk ReductionRuralScienceScientistSeriesStructureSubstance abuse problemTestingTimeTrainingUgandaUkraineUnited States National Institutes of HealthVolatilizationWest VirginiaWorkaccess restrictionsbehavioral adherencebiobehaviorcareerclinical practicedesignevidence baseexperienceglobal healthhigh risk behaviorhigh risk populationimplementation barriersimplementation scienceimprovedmHealthmeetingsnext generationopioid agonist therapyopioid epidemicopioid use disorderoverdose deathpatient orientedpatient oriented researchpre-exposure prophylaxispreventprogramsresearch data disseminationsexskillssymposiumtherapy developmenttreatment programtrend
项目摘要
Abstract
This revised K24 will enable me to optimize HIV prevention among opioid-dependent persons through three broad and
interrelated aims that include: (1) Mentoring a greater number of new patient-oriented researchers via UConn’s Institute for
Collaboration on Health, Intervention, and Policy (InCHIP) and the Yale AIDS Program, (2) Expanding my patient-oriented
research (POR) program to include several high priority domestic (e.g., rural West Virginia/Ohio) and international settings
(e.g., Uganda, Malaysia, and Ukraine), and (3) Engaging in structured training on critical issues surrounding the
implementation of evidence-based HIV prevention within clinical settings nationally and internationally that will complement
my POR skill set. The volatile opioid epidemic in the U.S. has taken an unimaginable toll, with 2.1 million Americans having
an opioid use disorder (OUD) and overdose deaths reaching 70,200 in 2017 alone, representing over a 400% increase in 15
years.1 In parallel, a number of HIV outbreaks among people who inject drugs (PWID)2 reversed a downward trend in this
group,1 reflecting the need to more effectively prevent HIV in this group, especially as patients with OUD transition from
prescription pain killers to injectable opioids.3 Consequently, the CDC has intensified efforts to reduce the number of new
HIV infections by more effectively and efficiently targeting PWID via: 1) reduced HIV risk behaviors, 2) increased adherence
and retention in treatment; and 3) promotion of health behaviors that benefit individual and public health. Although drug- and
sex-related HIV risk reduction and adherence are behaviors that are readily modifiable, interventions must be carefully
designed and situated in a range of patient-oriented settings in the US and internationally.4-8 I am in the process of expanding
my POR to focus on better identifying, understanding, and developing strategies at multiple levels to accommodate such
patients so that they can derive optimal HIV prevention benefits via the next generation of interventions (e.g., mHealth).9
Such strategies will need to reinforce adherence to PrEP and other biomedical prevention (e.g., opioid agonist therapies [OAT]
and syringe services programs [SSP]) alongside behavioral risk reduction. This will be especially important as priority domestic
and international communities struggle with their inability to overcome policy factors that limit or restrict access to the full
toolkit of HIV prevention (i.e., PrEP, OAT, SSP, behavioral interventions) for PWID. My ongoing (R01DA044867; Gilead
ISR-US-19-10641), recently completed (R01DA032290; R01DA022122), and future HIV prevention projects form the basis of
my POR and mentoring program as well as future domestic and international research collaborations. Each of the aims will
provide a wide range of opportunities for expanding my POR and for my mentees to develop the skill set they need to become
the next generation of HIV prevention scientists.
摘要
修订后的K24将使我能够通过三个广泛的,
相互关联的目标,包括:(1)通过康州大学的研究所指导更多的新的以病人为导向的研究人员,
健康,干预和政策合作(InCHIP)和耶鲁艾滋病计划,(2)扩大我的以病人为导向
研究(POR)计划包括几个高优先级的国内(例如,西弗吉尼亚州/俄亥俄州)和国际环境
(e.g.,乌干达、马来西亚和乌克兰),以及(3)就围绕
在国家和国际临床环境中实施循证艾滋病毒预防,
我的POR技能美国动荡的阿片类药物流行病造成了难以想象的损失,210万美国人
阿片类药物使用障碍(OUD)和过量死亡仅在2017年就达到70,200人,比15年增加了400%以上。
1与此同时,一些注射吸毒者(PWID)2中的艾滋病毒爆发扭转了这一下降趋势。
组,1反映了需要更有效地预防艾滋病毒在这一组,特别是作为患者与OUD过渡,
因此,疾病预防控制中心加大了努力,以减少新的
通过以下方式更有效地针对PWID感染艾滋病毒:1)减少艾滋病毒风险行为,2)增加依从性
3)促进有益于个人和公众健康的健康行为。虽然药物-和
与性有关的艾滋病毒风险降低和坚持是很容易改变的行为,干预措施必须谨慎,
在美国和国际上设计并位于一系列以患者为导向的环境中。4 -8我正在扩大
我的POR将重点放在更好地识别,理解和制定多层次的战略,以适应这些
患者,以便他们可以通过下一代干预措施(例如,mHealth). 9
这些战略将需要加强遵守PrEP和其他生物医学预防(例如,阿片类激动剂治疗[OAT]
和注射器服务计划[SSP])以及行为风险降低。这将是特别重要的,因为国内优先
和国际社会的斗争,他们无力克服政策因素,限制或限制充分获得
艾滋病毒预防工具包(即,PrEP、OAT、SSP、行为干预)用于PWID。我正在进行的(R 01 DA 044867;吉利德
ISR-US-19-10641),最近完成(R 01 DA 032290; R 01 DA 022122),未来的艾滋病毒预防项目构成了
我的POR和指导计划以及未来的国内和国际研究合作。每个目标将
提供广泛的机会,以扩大我的POR,并为我的学员发展他们需要成为的技能
下一代艾滋病预防科学家
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Integrating Cognitive Dysfunction Accommodation Strategies Into Behavioral Interventions for Persons on Medication for Opioid Use Disorder.
- DOI:10.3389/fpubh.2022.825988
- 发表时间:2022
- 期刊:
- 影响因子:5.2
- 作者:Mistler CB;Idiong CI;Copenhaver MM
- 通讯作者:Copenhaver MM
Integrating Cognitive Dysfunction Accommodation Strategies into an HIV Prevention Session: A 2-Arm Pilot Feasibility Study.
- DOI:10.3390/ijerph19159430
- 发表时间:2022-08-01
- 期刊:
- 影响因子:0
- 作者:Mistler, Colleen;Copenhaver, Michael
- 通讯作者:Copenhaver, Michael
Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS).
美沙酮维持治疗耻辱机制量表 (MMT-SMS) 的因素结构、内部信度和结构效度。
- DOI:10.1111/add.14799
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Smith,LaramieR;Mittal,MariaLuisa;Wagner,Karla;Copenhaver,MichaelM;Cunningham,ChinazoO;Earnshaw,ValerieA
- 通讯作者:Earnshaw,ValerieA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL COPENHAVER其他文献
MICHAEL COPENHAVER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL COPENHAVER', 18)}}的其他基金
Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP
针对 PrEP 注射吸毒者优化基于证据的艾滋病毒预防
- 批准号:
10818897 - 财政年份:2022
- 资助金额:
$ 18.95万 - 项目类别:
Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP
针对 PrEP 注射吸毒者优化基于证据的艾滋病毒预防
- 批准号:
10548320 - 财政年份:2022
- 资助金额:
$ 18.95万 - 项目类别:
Optimizing HIV Prevention Among Opioid-Dependent Persons
优化阿片类药物依赖者的艾滋病毒预防
- 批准号:
10425302 - 财政年份:2020
- 资助金额:
$ 18.95万 - 项目类别:
Optimizing HIV Prevention Among Opioid-Dependent Persons
优化阿片类药物依赖者的艾滋病毒预防
- 批准号:
10217091 - 财政年份:2020
- 资助金额:
$ 18.95万 - 项目类别:
Optimizing HIV Prevention Among Opioid-Dependent Persons
优化阿片类药物依赖者的艾滋病毒预防
- 批准号:
10083001 - 财政年份:2020
- 资助金额:
$ 18.95万 - 项目类别:
Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs
在吸毒高危人群中测试综合生物行为艾滋病毒初级预防干预措施
- 批准号:
10197074 - 财政年份:2017
- 资助金额:
$ 18.95万 - 项目类别:
Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs
在吸毒高危人群中测试综合生物行为艾滋病毒初级预防干预措施
- 批准号:
9410858 - 财政年份:2017
- 资助金额:
$ 18.95万 - 项目类别:
HIV Prevention and Adherence Among Priority Drug Using Populations
优先吸毒人群的艾滋病毒预防和依从性
- 批准号:
8628827 - 财政年份:2013
- 资助金额:
$ 18.95万 - 项目类别:
HIV Prevention and Adherence Among Priority Drug Using Populations
优先吸毒人群的艾滋病毒预防和依从性
- 批准号:
8812787 - 财政年份:2013
- 资助金额:
$ 18.95万 - 项目类别:
HIV Prevention and Adherence Among Priority Drug Using Populations
优先吸毒人群的艾滋病毒预防和依从性
- 批准号:
8541232 - 财政年份:2013
- 资助金额:
$ 18.95万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 18.95万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 18.95万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 18.95万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 18.95万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 18.95万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 18.95万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 18.95万 - 项目类别: